These studies suggest that rapalogs (mTORC1-specific) and active site dual-specificity mTOR inhibitors (asTORi) may differentially impact the tumor immune microenvironment and, potentially, sensitivity to combination immunotherapies. Here, MTOR is linked to neoplasm.